1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

23 May 2024
Admin
News Article

MIRA Pharmaceuticals and Memorial Sloan in Talks to Become Partner

MIRA Pharmaceuticals and Memorial Sloan Kettering in Talks to Partner on Preclinical Cancer Pain Model Utilizing New Oral Ketamine Analog

MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a pharmaceutical company focused on neurologic and neuropsychiatric disorders at the pre-clinical stage, has announced advanced discussions with Memorial Sloan Kettering Cancer Center (MSK).
The talks revolve around starting a preclinical study to evaluate Ketamir-2, MIRA's novel oral ketamine analog, for managing cancer-related pain and depression.

A Worthy Collaboration

This potential collaboration with MSK, a top cancer center globally, is seen as a significant validation of Ketamir-2's potential.
MIRA aims to broaden the application of its compound beyond ongoing studies in various mental health disorders.

Currently, MSK uses intravenous (IV) ketamine among other methods to treat refractory cancer pain. MIRA's oral ketamine analog offers a promising alternative due to its anticipated high oral bioavailability and lack of interaction with mu opioid receptors, potentially enhancing safety. Oral administration is more convenient and less invasive than IV treatments, potentially enabling at-home management. The collaboration seeks to assess Ketamir-2's effectiveness in alleviating cancer pain symptoms compared to non-oral ketamine administration in rodent models. Concurrently, MIRA explores Ketamir-2's effects on neuropathic pain in collaboration with Pharmaseed Ltd.

MIRA Pharmaceuticals, sees the potential partnership with MSK as highly validating, highlighting Ketamir-2's promise to transform oncology pain treatment.

MSK Expert on Ketamine-like Compounds

Dr. Amitabh Gulati, Director Chronic Pain at MSK and Board Member of Cancer Pain Research Consortium, acknowledges the promising role of ketamine-like compounds in cancer pain treatment.
He expresses excitement about MIRA's compounds potentially improving the lives of cancer + pain patients.

MIRA's novel oral ketamine analog aims to offer a safe and effective alternative for managing cancer pain and associated depression. Successful preclinical outcomes could accelerate FDA approval processes, paving the way for Investigational New Drug Application for Ketamir-2 and opening avenues for non-dilutive funding.

MIRA Pharmaceuticals, envisions a transformation in cancer pain management standards through this collaboration, emphasizing Ketamir-2's potential to address depression prevalent among cancer patients.

Cancer Pain Impacts

Cancer pain affects a significant portion of cancer patients, with studies indicating its prevalence and the high incidence of associated depression.
MIRA's innovative approach aims to alleviate these burdensome symptoms, potentially reshaping the landscape of oncology therapeutics.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!